Welcome to our dedicated page for Salarius Pharmaceuticals SEC filings (Ticker: SLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) SEC filings page aggregates the company’s official submissions to the U.S. Securities and Exchange Commission, providing structured access to the regulatory record behind its transformation and financing activities. These documents include current reports on Form 8‑K, registration statements on Form S‑1, and proxy materials on Schedule 14A, among others.
For this issuer, Form 8‑K filings are particularly important. They detail key events such as the completion of the strategic merger with Decoy Therapeutics, the issuance of Series A and Series B Non‑Voting Convertible Preferred Stock, underwritten public offerings of common stock and warrants, reverse stock split implementation, Nasdaq listing compliance updates and notices related to minimum bid price and equity standards. One 8‑K filed in early 2026 describes a Nasdaq notice regarding non-compliance with the minimum bid price requirement and the company’s stated intention to appeal a delisting determination to a Nasdaq Hearings Panel.
Registration statements on Form S‑1 and their amendments outline the terms of public offerings, including the number of shares, pre-funded warrants, Series A and Series B warrants and representative warrants, as well as intended use of proceeds such as advancing research and development programs and addressing Decoy promissory notes. The DEF 14A definitive proxy statement provides insight into corporate governance, board elections, executive compensation proposals and the conduct of the 2025 Annual Meeting of Stockholders.
On Stock Titan, these filings are paired with AI-powered summaries that explain complex structures in accessible language, highlighting elements such as the preferred stock conversion mechanics tied to the Decoy merger, conditions for Nasdaq initial listing standards, and the implications of reverse stock splits and listing notices. Users can quickly locate quarterly and annual reports when available, review historical and current 8‑Ks, and examine equity and warrant terms without reading every page of the original documents.
Because insider transaction information for SLRX, when filed on Form 4 or related ownership forms, also appears in the SEC’s EDGAR system, this page serves as a starting point for tracking changes in beneficial ownership alongside the broader corporate actions disclosed by Salarius and its successor branding as Decoy Therapeutics.
Salarius Pharmaceuticals reports that Nasdaq has notified the company it is not in compliance with the exchange’s minimum bid price rule because the closing bid for its common stock was below $1.00 per share for the last 30 consecutive business days. Due to a prior reverse stock split within the last year and the company’s status under a Mandatory Panel Monitor, Salarius is not eligible for the standard 180‑day grace period normally allowed to regain compliance.
Nasdaq has determined that the company’s securities will be scheduled for delisting from The Nasdaq Capital Market and suspended at the opening of business on January 9, 2026, with a Form 25‑NSE to remove them from listing and registration, unless Salarius appeals by January 7, 2026. The company intends to request a hearing before a Nasdaq Hearings Panel and present plans to regain compliance, but it states there is no assurance of a favorable outcome or that its securities will remain listed.
Salarius Pharmaceuticals, Inc. (SLRX) director reports stock purchase. A trust associated with director Arnold C. Hanish bought 5,000 shares of Salarius common stock on 11/20/2025 at a weighted average price of $0.7481 per share. These shares were acquired in multiple trades at prices ranging from $0.7437 to $0.75. After this transaction, the trust beneficially owned 5,015 shares of Salarius common stock, reported as indirect ownership on the Form 4.
Salarius Pharmaceuticals, Inc. (SLRX) filed an initial Form 3 reporting the equity holdings of its Chief Business Officer. The filing shows derivative securities rather than direct common stock ownership. The officer holds stock options to buy 5,061 shares of common stock at an exercise price of $4.9369 per share, expiring on 03/31/2032, and options to buy 8,318 shares at $50.2579 per share, expiring on 07/15/2030. The officer also holds Series A Preferred Shares that are convertible into common stock after stockholder approval and satisfaction of specified Nasdaq listing standards, and the preferred shares have no expiration date.
Salarius Pharmaceuticals, Inc. (SLRX) filed an initial Form 3 for its Chief Scientific Officer, reporting only derivative securities. The reporting person holds Series A Preferred Stock that is convertible into 141,734 shares of common stock. The Series A Preferred has no expiration date and will convert automatically into common shares after stockholder approval and satisfaction of specified Nasdaq listing standards.
The filing also reports two stock options for common stock: one covering 5,061 shares with an exercise price of
Salarius Pharmaceuticals (SLRX) disclosed the equity holdings of its Chief Executive Officer in connection with an event dated 11/12/2025. The CEO beneficially owns 16,666 shares of common stock directly. In addition, he holds Series A Preferred Stock that is convertible into 141,734 shares of common stock, which will automatically convert after stockholder approval and satisfaction of certain Nasdaq listing standards.
The CEO also holds derivative securities, including Series A and Series B warrants each exercisable for 16,666 shares of common stock at an exercise price of $1.5, with expiration dates on 11/12/2030 and 11/12/2026, respectively. He further holds stock options for 5,061 and 8,318 shares of common stock at exercise prices of $4.9369 and $50.2579, with some options exercisable only after stockholder approval and satisfaction of certain Nasdaq listing standards.
Salarius Pharmaceuticals (SLRX) reported an insider stock purchase by its Executive VP Finance and CFO, Mark J. Rosenblum. On 11/20/2025, he bought 20,000 shares of Salarius common stock at a price of $0.80 per share in an open-market transaction. After this purchase, he beneficially owns 20,177 shares of common stock, which includes 20 shares of unvested restricted stock granted on January 3, 2023. The reported post-transaction share amount reflects prior reverse stock splits that were effective on June 16, 2024 and August 17, 2025.
Salarius Pharmaceuticals, Inc. (SLRX) entered into new employment agreements with three senior leaders on November 18, 2025. Frederick E. Pierce will serve as Chief Executive Officer, Dr. Barbara Hibner as Chief Scientific Officer, and Peter Marschel as Chief Business Officer.
Each executive will receive an annual base salary of $225,000 and is eligible for a target annual bonus equal to 35% of base salary, based on performance objectives set by the board’s compensation committee. They will also be able to participate in the company’s standard executive benefit plans, such as medical, dental, life and disability coverage, subject to potential future changes by the company.
If an executive is terminated without cause or resigns for good reason, the agreement provides severance equal to $225,000 plus nine months of COBRA premium reimbursements at active employee rates, conditioned on signing a release of claims. Termination for cause, death, disability, or resignation without good reason limits payments to accrued salary, unused vacation, applicable benefits and reimbursable expenses.
Salarius Pharmaceuticals, Inc. clarifies that its common stock remains listed and trading on the Nasdaq Capital Market under the ticker “SLRX”. The company became aware that certain financial data platforms, including Yahoo Finance and CapIQ, incorrectly reported that it had been delisted effective November 13, 2025, and has contacted them to correct this error.
The company notes that it regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price rule, as of a letter dated September 4, 2025, and later regained compliance with Nasdaq Listing Rule 5550(b)(1), the equity standard, as of an October 10, 2025 letter. Salarius also highlights that, following completion of its strategic merger with Decoy Therapeutics, Inc. on November 13, 2025, it continues to meet the continued listing requirements and has not received any non-compliance notice from Nasdaq.
Salarius Pharmaceuticals (SLRX) filed its Q3 2025 10‑Q, reporting a net loss of $873,467 for the quarter and $3,540,825 for the nine months ended September 30, 2025. Operating expenses fell year over year, with research and development at $61,826 and general and administrative at $833,304 in Q3. Cash and cash equivalents were $4,809,680, and stockholders’ equity was $4,248,065.
The company disclosed substantial doubt about its ability to continue as a going concern, citing its lack of product revenue and recurring losses. Cash used in operations was $3,690,700 for the nine months, offset by $6,265,852 provided by financing activities.
Subsequent events: on November 12, 2025, Salarius closed its merger with Decoy Therapeutics and issued Series A and Series B non‑voting convertible preferred stock, together representing 4,814,106 underlying common shares subject to stockholder and Nasdaq approvals and beneficial ownership limits. The company also completed a public offering with approximately $6.3 million in net proceeds and reported 5,862,178 common shares outstanding as of November 12, 2025.
Salarius Pharmaceuticals (SLRX) completed a public offering and closed its merger with Decoy Therapeutics. The offering, led by Ladenburg Thalmann, raised approximately $6.3 million in net proceeds. It included 2,514,335 common shares, pre-funded warrants for up to 2,152,331 shares, and Series A and Series B warrants each exercisable for up to 4,666,666 shares. The underwriter exercised its option for 665,729 additional shares plus 699,999 Series A and 699,999 Series B warrants. Pricing was $1.50 per common share with accompanying warrants and $1.4999 per pre-funded warrant with accompanying warrants.
Proceeds will advance R&D, repay certain Decoy promissory notes, and fund general corporate needs. Series A and B warrants are immediately exercisable at $1.50; Series A expires in five years and Series B in one year. Representative warrants cover 266,620 shares at $2.325. After closing, 4,231,846 common shares were outstanding, with pre-funded warrants for 2,152,331 additional shares. The Decoy merger closed, and anti-dilution terms reset the Series A and B preferred conversion ratio to 2,800‑to‑1, with conversion contingent on stockholder and Nasdaq approvals and subject to 4.99% (or 9.99%) beneficial ownership limits.
FAQ
What is the current stock price of Salarius Pharmaceuticals (SLRX)?
What is the market cap of Salarius Pharmaceuticals (SLRX)?
